Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 3/20 | 0.59 |
| ▸ | POLG | P54098 | 2/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Psi-6130-Tp SCHEMBL12878130 | 1.00 | POLA1 (0.59) | POLA1POLGP2RY2P2RY4PDE4D | |
| Psi-6130-Tp SCHEMBL12849776 | 1.00 | POLA1 (0.59) | POLA1POLGP2RY2P2RY4PDE4D | |
| Psi-6130-Tp SCHEMBL21233069 | 1.00 | POLA1 (0.59) | POLA1POLGP2RY2P2RY4PDE4D | |
| Psi-6130-Tp SCHEMBL12799368 | 1.00 | POLA1 (0.59) | POLA1POLGP2RY2P2RY4PDE4D | |
| Psi-6130-Tp SCHEMBL15038016 | 1.00 | POLA1 (0.59) | POLA1POLGP2RY2P2RY4PDE4D | |
| SCHEMBL12849778 | 0.98 | POLA1 (0.61) | POLA1POLGP2RY2P2RY4PDE4D | |
| SCHEMBL12878128 | 0.98 | POLA1 (0.61) | POLA1POLGP2RY2P2RY4PDE4D | |
| SCHEMBL12799372 | 0.98 | POLA1 (0.61) | POLA1POLGP2RY2P2RY4PDE4D | |
| SCHEMBL471161 | 0.93 | POLG (0.57) | POLA1POLGP2RY2P2RY4PDE4D | |
| Gemcitabine Triphosphate SCHEMBL3468704 | 0.91 | POLA1 (0.69) | POLA1POLGP2RY2P2RY4PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4032897-B1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | GILEAD PHARMASSET LLC (US) | 2025-01-29 | — | — | EP | disclosed |
| EP-2604620-B9 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-2604620-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4032897-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | Gilead Pharmasset LLC (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-3521297-B1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | GILEAD PHARMASSET LLC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20190315792-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, LTD. (BB) | 2019-10-17 | — | — | US | disclosed |
| EP-3521297-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | Gilead Pharmasset LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10287311-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2019-05-14 | — | — | US | disclosed |
| EP-2604620-B1 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-2604620-A1 | Modified fluorinated nucleoside analogues | Gilead Pharmasset LLC (US) | 2013-06-19 | — | — | EP | disclosed |
| EP-2345658-A1 | Modified fluorinated nucleoside analogues | Pharmasset, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110038833-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20090036666-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080253995-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7429572-B2 | Modified fluorinated nucleoside analogues | PHARMASSET, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080070861-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| EP-1633766-A2 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | Pharmasset, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005003147-A2 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009737-A1 | Modified fluorinated nucleoside analogues | GILEAD SCIENCES, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070861-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | POLA1 2700/4885POLG 2915/4885P2RY2 378/4885 |
| US-10287311-B2 | Modified fluorinated nucleoside analogues | NSUN2, NT5C3B, METTL3 | POLA1 2700/4885POLG 2915/4885P2RY2 378/4885 |
| US-20090036666-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | POLA1 2700/4885POLG 2915/4885P2RY2 378/4885 |
| US-20190315792-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | POLA1 2700/4885POLG 2915/4885P2RY2 378/4885 |
| US-20050009737-A1 | Modified fluorinated nucleoside analogues | NSUN2, NT5C3B, METTL3 | POLA1 2700/4885POLG 2915/4885P2RY2 378/4885 |
| US-20110038833-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | POLA1 2700/4885POLG 2915/4885P2RY2 378/4885 |
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | POLA1 2700/4885POLG 2915/4885P2RY2 378/4885 |
| US-20080253995-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | POLA1 2700/4885POLG 2915/4885P2RY2 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.